Cencora Inc. ($COR) Stock Forecast: Down 2.4% Today

What is Cencora Inc.?

Cencora Inc (NYSE: COR) has recently acquired a majority stake in OneOncology for $5 billion, emphasizing its focus on specialized healthcare and long-term growth in the sector.

Why is Cencora Inc. going down?

COR stock is down 2.4% on Dec 16, 2025 16:00

• Factors contributing to the bearish movement in Cencora's stock (COR) today include:
• Concerns over the significant financial commitment of $5 billion for the OneOncology acquisition, impacting immediate financials.
• Investor caution regarding the initial EPS neutrality and timeline for positive contribution from the deal by mid-fiscal year 2027, despite positive analyst sentiment and raised price targets post-acquisition.
• Influence of recent market fluctuations and economic data on broader market sentiment, potentially affecting COR stock movement.
• Investor hesitancy as they wait to see the ultimate impact of OneOncology acquisition on Cencora's market position and financial performance, resulting in a temporary decline in stock price.

COR Price Chart

COR Technical Analysis

COR News

Cencora Moves To Take Full Control Of OneOncology

Cencora is acquiring nearly all of OneOncology for $5 billion, deepening its involvement in the growing US cancer care market. This move transitions Cencora from a minority to a controlling stake, aiming for long-term adjusted earnings growth despite initial neutrality. The deal signifies Cencora’s commitment to specialized healthcare and accelerates consolidation within the cancer care landscape.

https://finimize.com/content/cencora-moves-to-take-full-control-of-oneoncology

Cencora to buy majority of OneOncology's outstanding equity

Cencora plans to acquire most of OneOncology's outstanding equity that it doesn't already own, including shares from TPG, for roughly $5 billion. This acquisition values the cancer practice network OneOncology at approximately $7.4 billion.

https://www.axios.com/pro/health-tech-deals/2025/12/15/cencora-oneoncology-outstanding-equity

Cencora stock price target raised to $420 from $400 at Evercore ISI

Evercore ISI has increased its price target for Cencora Inc (NYSE:COR) to $420 from $400, maintaining an Outperform rating, following Cencora's strategic acquisition of the remaining stake in OneOncology. This move is seen as a "prudent use of capital" that is expected to be EPS neutral initially before contributing positively by mid-fiscal year 2027, leading to an upward revision of Cencora's long-term guidance. Other firms like TD Cowen, UBS, and Leerink Partners have also raised their price targets for Cencora, reflecting a positive analyst sentiment regarding the company's financial health, growth, and earnings potential.

https://m.investing.com/news/analyst-ratings/cencora-stock-price-target-raised-to-420-from-400-at-evercore-isi-93CH-4408535?ampMode=1

Cencora, Inc. entered into a definitive agreement to acquire an additional majority stake in OneOncology, LLC from TPG Inc. and other shareholders for $4.9 billion.

Cencora, Inc. has agreed to acquire an additional majority stake in OneOncology, LLC from TPG Inc. and other shareholders for $4.9 billion. The deal includes a $3.6 billion cash payment and the retirement of $1.3 billion in existing corporate debt, with OneOncology's affiliated practices and management retaining a minority interest. Cencora expects the transaction, which is subject to regulatory approvals and anticipated to close by the end of its fiscal 2026 second quarter, to be approximately neutral to its adjusted diluted EPS in the first twelve months post-closing.

https://www.marketscreener.com/news/cencora-inc-entered-into-a-definitive-agreement-to-acquire-an-additional-majority-stake-in-oneonco-ce7d50d9da8dff2d

Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus

This article highlights how Zacks Research methodologies have guided investors to market-beating returns, even amidst recent market fluctuations and economic data. It showcases several stocks, including Liquidia, Western Digital, and Johnson & Johnson, that have seen significant gains after receiving Zacks Rank upgrades, Outperform recommendations, or being featured on Zacks' specialized investment lists. The report also details the performance of various Zacks portfolios, emphasizing their consistent outperformance against the S&P 500 index.

https://www.tradingview.com/news/zacks:b4391073f094b:0-take-the-zacks-approach-to-beat-the-markets-liquidia-western-digital-johnson-johnson-in-focus/

Trending Today

Silver ($XAG) Commodity Forecast: Up 5.0% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 5.7% Today

Comcast Corporation Class A Common Stock ($CMCSA) Stock Forecast: Up 5.0% Today

National Oilwell Varco Inc. ($NOV) Stock Forecast: Down 5.1% Today

Phillips 66 ($PSX) Stock Forecast: Down 5.1% Today

Pfizer Inc. ($PFE) Stock Forecast: Down 5.1% Today

Humana Inc. ($HUM) Stock Forecast: Down 5.1% Today

Cytokinetics, Incorporated ($CYTK) Stock Forecast: Down 5.0% Today

S&P 500 Index ($SPX) Index Forecast: Down 0.8% Today

Apache Corporation ($APA) Stock Forecast: Down 5.1% Today

Cencora Inc. Price History

23.08.2025 - COR Stock was up 5.1%

• The strong bullish movement in Cencora (NYSE: COR) today may be linked to its impressive long-term outperformance of the market, boasting an average annual return of 20.51% over the past decade.
• Investors seem to be drawn to COR because of its consistent growth and its ability to produce returns that surpass the market average significantly.
• The coverage of COR's exceptional performance in recent times could have further piqued investor interest, leading to an increase in the stock price.

03.00.2025 - COR Stock was up 3.4%

• Market expectations point towards a potential increase in COR stock, reflecting optimistic investor sentiment.
• COR has outperformed the market by 4.82% annually over the last decade, highlighting its robust historical performance.
• Today's positive uptick in COR may be linked to the favorable outlook in the options market and its consistent market outperformance.

08.04.2025 - COR Stock was down 4.2%

• Despite surpassing Q2 earnings and revenue estimates, COR witnessed a bearish movement in the market.
• Concerns about revenue sustainability and competition in the pharmaceutical sector may have contributed to the market's negative reaction.
• Investor caution regarding the company's growth sustainability could result in profit-taking and a bearish stock price trend.
• Broader economic factors and sector-specific challenges in the pharmaceutical industry might also influence the market movement.

08.04.2025 - COR Stock was down 5.2%

• Despite surpassing Q2 earnings and revenue expectations, COR observed a decline in its stock price today.
• The high demand for weight loss drugs and specialty products might not have sustained the stock's elevated value, resulting in profit-taking by traders.
• The market's response could be due to concerns regarding future growth prospects or uncertainties about the company's trajectory.
• Investors may have anticipated stronger results or guidance from COR, triggering a stock sell-off despite its recent accomplishments in the healthcare solutions industry.

15.08.2025 - COR Stock was down 1.9%

• The factors behind the bearish movement in COR include:
• Investors taking profits following a recent uptrend.
• Worries about decreased demand for cloud computing services.
• Negative impact of overall market sentiment on tech stocks.
• Absence of specific positive news or catalysts to drive buying activity for COR.

05.01.2025 - COR Stock was down 0.3%

• The bearish movement in COR stock today could be attributed to profit-taking by investors despite the company surpassing Q1 earnings and revenue estimates.
• The strong performance in the U.S. Healthcare Solutions segment might have been already priced in, leading to a sell-off.
• The stiff competition could be causing concerns among investors, leading to the bearish trend.
• The stock's historical outperformance and market capitalization may have set high expectations, and any deviation from this trajectory could trigger a negative market reaction.

05.10.2025 - COR Stock was down 0.1%

• Despite Cencora (COR) surpassing earnings and revenue estimates for Q4, the stock exhibited bearish movement.
• Investors may have had higher expectations or anticipated growth projections beyond the reported numbers, resulting in a sell-off.
• Market sentiment could have been swayed by external factors such as macroeconomic uncertainties or industry shifts, rather than the company's financial achievements.
• Some investors might have opted to take profits after the positive news, leading to a temporary decline in the stock price.

07.04.2025 - COR Stock was up 5.7%

• COR outperformed Q2 earnings and revenue expectations, signaling robust financial results.
• The U.S. Healthcare Solutions segment's favorable outlook is anticipated to be a key driver of COR's success.
• Analysts hold a positive view on COR's crucial metrics for the quarter, indicating a favorable path for the company.
• Investors reacted favorably to the strong performance and growth potential of COR, leading to the uptrend in the stock price.

16.11.2025 - COR Stock was down 2.4%

• Factors contributing to the bearish movement in Cencora's stock (COR) today include:
• Concerns over the significant financial commitment of $5 billion for the OneOncology acquisition, impacting immediate financials.
• Investor caution regarding the initial EPS neutrality and timeline for positive contribution from the deal by mid-fiscal year 2027, despite positive analyst sentiment and raised price targets post-acquisition.
• Influence of recent market fluctuations and economic data on broader market sentiment, potentially affecting COR stock movement.
• Investor hesitancy as they wait to see the ultimate impact of OneOncology acquisition on Cencora's market position and financial performance, resulting in a temporary decline in stock price.

06.07.2025 - COR Stock was down 6.4%

• The bearish movement in COR stock today may be linked to the market's reaction to the company's Q3 earnings, despite exceeding earnings and revenue expectations. Here's a breakdown of the situation:
• The market could have anticipated more robust results given COR's consistent outperformance, leading to a sell-off.
• Worries about international challenges impacting Q3 figures might have unsettled investors, overshadowing the positive earnings beats.
• Investors expecting a significant earnings beat based on Wall Street projections might have felt let down, resulting in a decline in the stock's value.
• While hopes were high for COR's earnings growth, the market's response today indicates that even surpassing estimates does not always guarantee a positive reaction from investors.

04.03.2025 - COR Stock was down 0.7%

• Despite being considered a safe bet during market volatility, COR faced a strong bearish movement today.
• The comparison with other medical stocks like Intensity Therapeutics Inc. may have highlighted weaknesses in COR's performance, contributing to the bearish trend.
• The overall market volatility, potentially influenced by external factors, could have also played a role in the bearish movement of COR today.

31.06.2025 - COR Stock was down 2.4%

• The decline in COR's stock today could be due to profit-taking by investors who were possibly anticipating a positive earnings outcome.
• Comparisons with McKesson (MCK) in the medical sector may have impacted investor sentiment, resulting in a sell-off of COR as it might have shown lower performance compared to its sector so far this year.
• Investors might be reassessing their holdings in COR based on its performance relative to McKesson, potentially influencing the downward trend in the stock.